Reveal the Regulation Patterns of Prognosis-Related miRNAs and lncRNAs Across Solid Tumors in the Cancer Genome Atlas

Abstract

Background: The dysregulation of non-coding RNAs (ncRNAs) such as miRNAs and lncRNAs are associated with the pathogenesis and progression in multiple cancers including solid tumors. Comprehensive investigations of prognosis-related ncRNA markers could promote the development of therapeutic strategies for solid tumors, but rarely reported. Methods: By taking advantage of The Cancer Genome Atlas (TCGA), pan-cancer prognosis analysis (PCPA) models were firstly constructed based on miRNA and lncRNA expression profiles of 8,450 samples in 19 solid tumors. Further, the co-occurrence and exclusivity among ncRNA markers were systematically analyzed for different cancers. Results: In identified ncRNA makers, 71% of the miRNA markers were shared in multiple cancers, whereas 96% of the lncRNA markers were cancer-specific. Moreover, to analyze the regulation patterns of prognosis-related ncRNAs at the pan-cancer level, miRNA markers were further annotated into eight carcinogenic pathways. Results represented that approximately 86% of these miRNA markers could regulate the PI3K-Akt signaling pathway, while only 48% for the Notch signaling pathway. Finally, among 126 common genes that participated in eight carcinogenic pathways, BCL2, CSNK2A1, EGFR, PDGFRA, and VEGFA were proposed as potential drug targets for multiple cancers. Conclusion: The prognosis analysis and regulation characteristics of ncRNAs presented in this study may help to facilitate the discovery of anti-cancer drugs for multiple solid tumors.

In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer

“…a-f Different CDK6 expression patients' sensitivity to cisplatin (P < 0.001), gemcitabine (P < 0.001), methotrexate (P > 0.05), mitomycin C (P < 0.001), paclitaxel (P < 0.001), and vinblastine (P < 0.001). g-l Different risk patients' sensitivity to cisplatin (P < 0.001), gemcitabine (P < 0.001), methotrexate (P > 0.05), mitomycin C (P > 0.05), paclitaxel (P < 0.01), and vinblastine (P > 0.05) gastrointestinal cancer (Yin et al 2020). RPS6 may be an independent prognostic marker for metastatic renal cell carcinoma (Fang et al 2017).…”

“…IGF1 affects the incidence and mortality of tumors (Levine et al 2014 ) and survival from breast tumors (Zhang et al 2009 ). PDGFRA may be an anti-cancer drug target in gastrointestinal cancer (Yin et al 2020 ). RPS6 may be an independent prognostic marker for metastatic renal cell carcinoma (Fang et al 2017 ).…”